{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:03:54Z","timestamp":1777575834932,"version":"3.51.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Specific immune tolerance of transplanted organs in association with either transient or sustained lymphohematopoietic chimerism has been demonstrated in several preclinical animal models and clinically in patients who are full donor chimeras after hematopoietic stem cell transplantation and subsequently received kidney transplants from the same donor. Most recently, tolerance induction has been extended to patients in whom chimerism was intentionally induced at the time of kidney transplantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>Twenty years ago, we reported the first successful histocompatibility leukocyte antigen-matched sibling donor bone marrow and kidney transplant following nonmyeloablative conditioning in a patient with multiple myeloma and end-stage renal disease (ESRD). After 2 decades, she has normal renal function in the absence of ongoing systemic immunosuppressive therapy. Nine patients have subsequently undergone similar treatment for multiple myeloma with ESRD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>In the initial patient, hematopoietic chimerism was detectable for only 105 days after the transplant. In subsequent patients, chimerism detection ranged from 49 days to &gt;14 years. Nevertheless, a long remission of the myeloma and long-term immunosuppression-free survival of the kidney allograft were achieved in 7 of the 10 patients, 5 of whom currently survive.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>This initial patient demonstrated the feasibility of performing combined histocompatibility leukocyte antigen-matched, sibling donor bone marrow and kidney transplantation for ESRD due to multiple myeloma. This experience paved the way for extending the initial trial to 9 additional patients with multiple myeloma and ESRD and, more recently, to tolerance induction strategies involving combined bone marrow and kidney transplantation for patients with and without an underlying malignancy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000002669","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T21:06:32Z","timestamp":1551387992000},"page":"2366-2372","source":"Crossref","is-referenced-by-count":28,"title":["Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease: Lessons Learned"],"prefix":"10.1097","volume":"103","author":[{"given":"Thomas R.","family":"Spitzer","sequence":"first","affiliation":[{"name":"Bone Marrow Transplant Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA."},{"name":"Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Tolkoff-Rubin","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA."},{"name":"Renal Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Benedict","family":"Cosimi","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA."},{"name":"Transplantation Unit, Department of Surgery, Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"McAfee","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA."},{"name":"Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bimalangshu R.","family":"Dey","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA."},{"name":"Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA."},{"name":"Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Delmonico","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA."},{"name":"Transplantation Unit, Department of Surgery, Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Sykes","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, Columbia University Medical Center."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Sachs","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA."},{"name":"Center for Transplant Science, Department of Surgery, Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Kawai","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA."},{"name":"Transplantation Unit, Department of Surgery, Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1084\/jem.147.3.700","article-title":"Transplantation tolerance in adult rats using total lymphoid irradiation: permanent survival of skin, heart, and marrow allografts.","volume":"147","author":"Slavin","year":"1978","journal-title":"J Exp Med"},{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0167-5699(88)91352-7","article-title":"Mixed allogeneic chimerism as an approach to transplantation tolerance.","volume":"9","author":"Sykes","year":"1988","journal-title":"Immunol Today"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1084\/jem.169.2.493","article-title":"Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen.","volume":"169","author":"Sharabi","year":"1989","journal-title":"J Exp Med"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007890-199608150-00014","article-title":"Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Peripheral mechanisms do not contribute to maintenance of tolerance.","volume":"62","author":"Khan","year":"1996","journal-title":"Transplantation"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00007890-199501000-00018","article-title":"Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys.","volume":"59","author":"Kawai","year":"1995","journal-title":"Transplantation"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/bbmt.2001.v7.pm11787527","article-title":"Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.","volume":"7","author":"Mapara","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"a015529","DOI":"10.1101\/cshperspect.a015529","article-title":"Induction of tolerance through mixed chimerism.","volume":"4","author":"Sachs","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1097\/00007890-200106150-00031","article-title":"Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up.","volume":"71","author":"Sellers","year":"2001","journal-title":"Transplantation"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00007890-199908270-00006","article-title":"Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism.","volume":"68","author":"Spitzer","year":"1999","journal-title":"Transplantation"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJMoa071074","article-title":"HLA-mismatched renal transplantation without maintenance immunosuppression.","volume":"358","author":"Kawai","year":"2008","journal-title":"N Engl J Med"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMc1213779","article-title":"HLA-mismatched renal transplantation without maintenance immunosuppression.","volume":"368","author":"Kawai","year":"2013","journal-title":"N Engl J Med"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/TP.0b013e31820a3068","article-title":"Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease.","volume":"91","author":"Spitzer","year":"2011","journal-title":"Transplantation"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2004.05328.x","article-title":"Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation.","volume":"128","author":"Dey","year":"2005","journal-title":"Br J Haematol"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2002-12-3949","article-title":"Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma.","volume":"102","author":"Rubio","year":"2003","journal-title":"Blood"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4049\/jimmunol.175.2.665","article-title":"Mechanisms of the antitumor responses and host-versus-graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: a critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived IFN-gamma-producing CD8+ T cells.","volume":"175","author":"Rubio","year":"2005","journal-title":"J Immunol"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2006.03.004","article-title":"Role of indirect allo- and autoreactivity in anti-tumor responses induced by recipient leukocyte infusions (RLI) in mixed chimeras prepared with nonmyeloablative conditioning.","volume":"120","author":"Rubio","year":"2006","journal-title":"Clin Immunol"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.exphem.2006.04.022","article-title":"Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.","volume":"34","author":"Saito","year":"2006","journal-title":"Exp Hematol"},{"key":"R18-20231002","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1111\/j.1600-6143.2006.01434.x","article-title":"Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses.","volume":"6","author":"Fudaba","year":"2006","journal-title":"Am J Transplant"},{"key":"R19-20231002","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1600-6143.2011.03566.x","article-title":"Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow\/kidney transplantation.","volume":"11","author":"Andreola","year":"2011","journal-title":"Am J Transplant"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"pii:e86419","DOI":"10.1172\/jci.insight.86419","article-title":"Induced regulatory T cells in allograft tolerance via transient mixed chimerism.","volume":"1","author":"Hotta","year":"2016","journal-title":"JCI Insight"},{"key":"R21-20231002","doi-asserted-by":"crossref","first-page":"pii:124086","DOI":"10.1172\/jci.insight.124086","article-title":"Early expansion of donor-specific Tregs in tolerant kidney transplant recipients.","volume":"3","author":"Savage","year":"2018","journal-title":"JCI Insight"},{"key":"R22-20231002","doi-asserted-by":"crossref","first-page":"272ra10","DOI":"10.1126\/scitranslmed.3010760","article-title":"Tracking donor-reactive T cells: evidence for clonal deletion in tolerant kidney transplant patients.","volume":"7","author":"Morris","year":"2015","journal-title":"Sci Transl Med"},{"key":"R23-20231002","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.humimm.2017.12.011","article-title":"Immune monitoring of transplant patients in transient mixed chimerism tolerance trials.","volume":"79","author":"Sykes","year":"2018","journal-title":"Hum Immunol"},{"key":"R24-20231002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-018-0553-8","article-title":"Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017.","volume":"18","author":"Yin","year":"2018","journal-title":"Cancer Cell Int"},{"key":"R25-20231002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R26-20231002","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/j.1600-6143.2011.03572.x","article-title":"Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts.","volume":"11","author":"Farris","year":"2011","journal-title":"Am J Transplant"},{"key":"R27-20231002","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/ajt.13091","article-title":"Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation.","volume":"15","author":"Scandling","year":"2015","journal-title":"Am J Transplant"},{"key":"R28-20231002","doi-asserted-by":"crossref","first-page":"124ra28","DOI":"10.1126\/scitranslmed.3003509","article-title":"Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation.","volume":"4","author":"Leventhal","year":"2012","journal-title":"Sci Transl Med"},{"key":"R29-20231002","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.","volume":"109","author":"Chanan-Khan","year":"2007","journal-title":"Blood"},{"key":"R30-20231002","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.24335","article-title":"Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.","volume":"91","author":"Dimopoulos","year":"2016","journal-title":"Am J Hematol"},{"key":"R31-20231002","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/bmt.2017.198","article-title":"Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.","volume":"52","author":"Mahindra","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"R32-20231002","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjh.12818","article-title":"Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma.","volume":"165","author":"Murphy","year":"2014","journal-title":"Br J Haematol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:29:39Z","timestamp":1696224579000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002669","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}